Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmunityBio, Inc. (Nasdaq: IBRX) on April 1, 2021, covering events that occurred on March 29, 2021. The filing addresses significant changes to the Company's Board of Directors, including resignations and new appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
Resignations
- John C. Thomas Jr. and Frederick W. Driscoll resigned from the Board of Directors effective March 29, 2021.
- Mr. Thomas also resigned as chairperson of the audit and related party transaction committees and as a member of the compensation committee.
- Mr. Driscoll resigned from the audit, compensation, and related party transaction committees.
- The resignations were for personal reasons and were not the result of any disagreement with the Company regarding operations, policies, or practices.
Appointments
- Linda Maxwell, M.D., M.B.A. was appointed to the Board effective immediately. She will serve as a member of the audit committee and chairperson of the compensation committee. Her term expires at the 2021 annual meeting of stockholders.
- Richard Adcock, the Company's Chief Executive Officer, was appointed to the Board effective immediately. His term expires at the 2021 annual meeting of stockholders.
Compensation and Management Commentary
Dr. Maxwell is entitled to cash compensation under the Outside Director Compensation Policy, which includes:
- $50,000 annually for Board service.
- $10,000 annually for audit committee membership.
- $15,000 annually for chairing the compensation committee.
- Reimbursement for reasonable expenses.
- Potential equity compensation consistent with past practice.
Mr. Adcock, as an employee director, will not receive additional compensation for his Board appointment. The Company issued a press release on April 1, 2021, announcing these appointments.
Investor Verification Checklist
- Verify the effective date of the Board composition changes (March 29, 2021).
- Confirm the specific committee assignments for the new director, Dr. Linda Maxwell.
- Review the attached press release (Exhibit 99.1) for additional context on the appointments.
- Note that no financial data or operational metrics are disclosed in this specific filing.